Galectin-3 in Predicting Mortality of Heart Failure: A Systematic Review and Meta-Analysis

Authors

  • Chenxia Wu Department of Cardiology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China
  • Zhengtian Lv Department of Cardiology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China
  • Xinyi Li Department of Cardiology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China
  • Xinbing Zhou Department of Cardiology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China
  • Wei Mao Department of Cardiology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China
  • Min Zhu Department of Cardiology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China

DOI:

https://doi.org/10.1532/hsf.3547

Keywords:

galectin-3, heart failure, mortality, meta-analysis

Abstract

Background: In recent years, galectin-3, an inflammatory marker, has been demonstrated to be closely related to cardiac fibrosis and heart failure. The purpose of this systematic review and meta-analysis is to define galectin-3 in predicting mortality of heart failure.

Methods: PubMed, Embase, and the Cochrane Library were searched. A total of 1540 studies were identified, and of these studies, 19 involving 9217 patients were included in our meta-analysis.

Results: The diagnostic hazard ratios of galectin-3 in predicting mortality in chronic heart failure patients was 1.13 (95% CI,:1.07-1.21 ) and 2.17 (95% CI:1.27-3.08) in acute heart failure (HF) patients.

Conclusions: Our meta-analysis shows that elevated levels of galectin-3 are associated with higher mortality in both acute and chronic heart failure patients.

References

Anand IS, et al. 2013. Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT. Eur J Heart Fail. 15(5): p. 511-8.

Behnes M, et al. 2016. Triple head-to-head comparison of fibrotic biomarkers galectin-3, osteopontin and gremlin-1 for long-term prognosis in suspected and proven acute heart failure patients. Int J Cardiol. 203: p. 398-406.

Beltrami M, et al. 2016. Additional value of Galectin-3 to BNP in acute heart failure patients with preserved ejection fraction. Clin Chim Acta. 457: p. 99-105.

Benjamin EJ, et al. 2019. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation. 139(10): p. e56-e528.

Binas D, et al. 2018. The prognostic value of sST2 and galectin-3 considering different aetiologies in non-ischaemic heart failure. Open Heart. 5(1): p. e000750.

Brown RD, et al. 2005. The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. Annu Rev Pharmacol Toxicol. 45: p. 657-87.

Carrasco-Sanchez FJ, et al. 2013. Predictive value of serum galectin-3 levels in patients with acute heart failure with preserved ejection fraction. Int J Cardiol. 169(3): p. 177-82.

Chen YS, et al. 2016. Using the galectin-3 test to predict mortality in heart failure patients: a systematic review and meta-analysis. Biomark Med. 10(3): p. 329-42.

Clementy N, et al. 2018. Galectin-3 level predicts response to ablation and outcomes in patients with persistent atrial fibrillation and systolic heart failure. PLoS One. 13(8): p. e0201517.

Cui Y, et al. 2018. Differential and Predictive Value of Galectin-3 and Soluble Suppression of Tumorigenicity-2 (sST2) in Heart Failure with Preserved Ejection Fraction. Med Sci Monit. 24: p. 5139-5146.

de Boer RA, et al. 2009. Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail. 11(9): p. 811-7.

de Boer RA, et al. 2011. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med. 43(1): p. 60-8.

Diez J. 2017. Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system: implications for therapy. Eur J Heart Fail. 19(2): p. 167-176.

Felker GM, et al. 2012. Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study. Circ Heart Fail. 5(1): p. 72-8.

Fiuzat M, et al. 2014. Relationship between galectin-3 levels and mineralocorticoid receptor antagonist use in heart failure: analysis from HF-ACTION. J Card Fail. 20(1): p. 38-44.

French B, et al. 2016. Prognostic Value of Galectin-3 for Adverse Outcomes in Chronic Heart Failure. J Card Fail. 22(4): p. 256-62.

Gaggin HK and Januzzi JL, Jr. 2013. Biomarkers and diagnostics in heart failure. Biochim Biophys Acta. 1832(12): p. 2442-50.

Gruson D, et al. 2014. Measurement of Galectin-3 with the ARCHITECT assay: Clinical validity and cost-effectiveness in patients with heart failure. Clin Biochem. 47(12): p. 1006-9.

Gullestad L, et al. 2012. Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Eur Heart J. 33(18): p. 2290-6.

Imran TF, et al. 2017. Meta-Analysis of the Usefulness of Plasma Galectin-3 to Predict the Risk of Mortality in Patients With Heart Failure and in the General Population. Am J Cardiol. 119(1): p. 57-64.

Jabagi H, et al. 2019. Biomarkers in the Diagnosis, Management, and Prognostication of Perioperative Right Ventricular Failure in Cardiac Surgery-Are We There Yet? J Clin Med. 8(4).

Januzzi JL, Jr. et al. 2005. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol. 95(8): p. 948-54.

Kim H, et al. 2007. Expression and immunohistochemical localization of galectin-3 in various mouse tissues. Cell Biol Int. 31(7): p. 655-62.

Lala RI, et al. 2018. Galectin-3 as a marker for clinical prognosis and cardiac remodeling in acute heart failure. Herz. 43(2): p. 146-155.

Levy WC, et al. 2006. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation. 113(11): p. 1424-33.

Li X, et al. 2018. Therapeutic inhibition of galectin3 improves cardiomyocyte apoptosis and survival during heart failure. Mol Med Rep. 17(3): p. 4106-4112.

Lok DJ, et al. 2013. Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin Res Cardiol. 102(2): p. 103-10.

Lopez-Andres N, et al. 2012. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial. Eur J Heart Fail. 14(1): p. 74-81.

Motiwala SR, et al. 2013. Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. Eur J Heart Fail. 15(10): p. 1157-63.

Mueller T, et al. 2016. Diagnostic and prognostic accuracy of galectin-3 and soluble ST2 for acute heart failure. Clin Chim Acta. 463: p. 158-164.

Nicolas D, et al. 2016. [Respiratory failure caused by amyloid myopathy]. Med Clin (Barc). 146(5): p. e25-6.

Sharma UC, et al. 2004. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 110(19): p. 3121-8.

Tang WH, et al. 2011. Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am J Cardiol. 108(3): p. 385-90.13.

Testa M, et al. 2018. The Predictive Value of Plasma Brain Natriuretic Peptide and Galectin-3 in Elderly Patients Admitted for Heart Failure. Diseases. 6(4).

The L. 2018. Heart failure: the need for improved treatment and care. Lancet. 392(10146): p. 451.

van Vark LC, et al. 2017. Prognostic Value of Serial Galectin-3 Measurements in Patients With Acute Heart Failure. J Am Heart Assoc. 6(12).

Yu X, et al. 2015. Prognostic value of plasma galectin-3 levels in patients with coronary heart disease and chronic heart failure. Int Heart J. 56(3): p. 314-8.

Zhang M, et al. 2018. Comparison of multiple biomarkers for mortality prediction in patients with acute heart failure of ischemic and nonischemic etiology. Biomark Med. 12(11): p. 1207-1217.

Published

2021-03-30

How to Cite

Wu, C., Lv, Z., Li, X., Zhou, X., Mao, W., & Zhu, M. (2021). Galectin-3 in Predicting Mortality of Heart Failure: A Systematic Review and Meta-Analysis. The Heart Surgery Forum, 24(2), E327-E332. https://doi.org/10.1532/hsf.3547

Issue

Section

Articles